Case Study: Management of Post-Parotidectomy Neuropathic Pain with Sativex

Authors

  • Patrick T. Yang The University of British Columbia, Faculty of Medicine
  • May Ong-Lam St. Paul's Pain Clinic, UBC

Abstract

Effective treatment and management of neuropathic pain has been limited.  A THC:CBD endocannabinoid system modulator (Sativex) buccomucosal spray is used in this case study to successfully treat a patient suffering from neuropathic pain.  Furthermore, this particular case study shows that the cannabinoids may be effective, at least in part, through a central mechanism to relieve the allodynia.

            This patient’s allodynia was treated with Sativex buccomucosal spray (one to two sprays, three times a day).  Six weeks later, the patient returned with all symptoms alleviated and transient decrease in alertness as the only side effect.  Two years since the start of sativex treatment for allodynia, the patient has not had any relapse and is now working and fully functional.  

 

Author Biography

Patrick T. Yang, The University of British Columbia, Faculty of Medicine

Graduated from UBC Microbiology & Immunology 2005

UBC Medicine Class of 2011

Additional Files

Published

2010-10-03

Issue

Vol. 2 No. 1 (2010): Interprofessionalism: Making Connections

Section

Case and Elective Reports